DrugPatentWatch Database Preview
Exelixis Company Profile
What is the competitive landscape for EXELIXIS, and what generic alternatives to EXELIXIS drugs are available?
EXELIXIS has two approved drugs.
There are six US patents protecting EXELIXIS drugs.
Summary for Exelixis
| US Patents: | 6 |
| Tradenames: | 2 |
| Ingredients: | 1 |
| NDAs: | 2 |
Drugs and US Patents for Exelixis
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-001 | Apr 25, 2016 | RX | Yes | No | 7,579,473 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Exelixis | COMETRIQ | cabozantinib s-malate | CAPSULE;ORAL | 203756-001 | Nov 29, 2012 | RX | Yes | Yes | 7,579,473 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-002 | Apr 25, 2016 | RX | Yes | No | 7,579,473 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Exelixis | COMETRIQ | cabozantinib s-malate | CAPSULE;ORAL | 203756-001 | Nov 29, 2012 | RX | Yes | Yes | 9,717,720 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-003 | Apr 25, 2016 | RX | Yes | Yes | 10,039,757 | ➤ Sign Up | ➤ Sign Up | ||||
| Exelixis Inc | CABOMETYX | cabozantinib s-malate | TABLET;ORAL | 208692-003 | Apr 25, 2016 | RX | Yes | Yes | 8,497,284 | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for Exelixis Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Israel | 234097 | ➤ Sign Up |
| Netherlands | 300678 | ➤ Sign Up |
| Japan | 2012515220 | ➤ Sign Up |
| European Patent Office | 2392565 | ➤ Sign Up |
| Japan | 2010265302 | ➤ Sign Up |
| Japan | 2013531045 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Exelixis Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2014033 | Lithuania | ➤ Sign Up | PRODUCT NAME: CABOZANTINIBUM; REGISTRATION NO/DATE: EU/1/13/890/001 - EU/1/13/890/003 20140321 |
| 2014 00039 | Denmark | ➤ Sign Up | PRODUCT NAME: CABOZANTINIB, INKLUSIVE FARMACEUTISK ACCEPTABLE SALTE HERAF, HERUNDER CABOZANTINIB (S)-MALAT; REG. NO/DATE: EU/1/13/890/001-003 20140321 |
| 508 | Luxembourg | ➤ Sign Up | PRODUCT NAME: CABOZANTINIB ET TOUTES LES FORMES THERAPEUTIQUEMENT EQUIVALENTES QUI EN DERIVENT TELLES QUE PROTEGEES PAR LE BREVET DE BASE, Y COMPRIS LES SELS PHARMACEUTIQUEMENT ACCEPTABLES. FIRST REGISTRATION: 20140326 |
| C0067 | France | ➤ Sign Up | PRODUCT NAME: CABOZANTINIB ET TOUTE FORME THERAPEUTIQUEMENT EQUIVALENTE COUVERTE PAR LE BREVET DE BASE,INCLUANT SES SELS PHARMACEUTIQUEMENT EQUIVALENTS.; REGISTRATION NO/DATE: EU/1/13/890 20140326 |
| 0 50007-2014 | Slovakia | ➤ Sign Up | PRODUCT NAME: CABOZANTINIB; REGISTRATION NO/DATE: EU/1/13/890/001 - EU/1/13/890/003 20140326 |
| 00678 | Netherlands | ➤ Sign Up | PRODUCT NAME: CABOZANTINIB EN ELKE THERAPEUTISCH EQUIVALENTE VORM DAARVAN ZOALS BESCHERMD DOOR HET BASISOCTROOI, WAARONDER FARMACEUTISCH AANVAARDBARE ZOUTEN; REGISTRATION NO/DATE: EU/1/13/890/001-003 20140326 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
